BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
  • Home
  • Chronic Pain Claims
    • CRPS Compensation
    • Fibromyalgia Compensation
    • Myofascial Pain Syndrome Compensation
    • Somatic Symptom Disorder Compensation
    • Neuropathic Pain Compensation
    • Functional Neurological Disorder Compensation
    • Chronic Pain Syndrome Compensation
  • Case Studies
  • Chronic Pain Blog
  • Testimonials
  • Contact Us

Home » New trial of Neridronate for CRPS announced

Complex Regional Pain Syndrome Jun 25th, 2018
Neridronate infusion for CRPS

New trial of Neridronate for CRPS announced

We have written previously of the benefits experienced by some people suffering CRPS who have undergone infusions of the bisphosphonate drug, Neridronate (also referred to as neridronic acid). Bisphosphonates prevent or slow down the loss of bone density.

Grünenthal

German pharmaceutical company Grünenthal, which is developing Neridronate for the US market, has commenced two Phase III clinical trials of the drug.

In a press release, Grünenthal’s chief executive, Gabriel Baertschi, said:

“There is a huge unmet medical need in CRPS as this condition may result in loss of the physical function and may lead to significant and sometimes permanent disability. Neridronate has been granted Breakthrough Therapy and Fast Track designation by the FDA and our pivotal phase III development program is the next step to investigate neridronate’s potential to make a difference in the lives of patients affected by this debilitating disease.”

Professor Claudia Sommer, International Coordinating Investigator for one of the trials added:

“I’m excited to be part of a pivotal phase III efficacy trial in CRPS. Currently, there is no approved treatment available and affected patients face a permanently high pain level and immense restrictions in their daily life. If the efficacy of neridronate is confirmed, quality of life of the patients could be significantly improved.”

Phase III

Phase III trials are those that compare the efficacy and safety of a new treatment with the standard treatment for the condition. Following a successful Phase III trial a drug is usually granted a licence before moving to Phase IV to further study and assess longer term risks and side effects.

The two trials will investigate the drug’s effect on pain, as well as other symptoms of CRPS such as allodynia and oedema. Around 360 patients will be involved, each undergoing treatment over a twelve week period, with the degree of any improvement being assessed.

Italy

Neridronate is currently licensed for treatment in Italy. As reported previously, research conducted there in 2012 produced some startlingly positive results. However, those trials involved CRPS Type 1 only and all participants had been suffering from the condition for less than 4 months. As Libby Parfitt stated in her excellent article:

“The Italian team freely admit that those who’ve had CRPS for longer may not experience the same results but they claim that the treatment is “still effective” even for those who’ve had CRPS for years. There are no published papers on trials involving neridronate with patients who have longstanding CRPS, but there are papers on other bisphosphonates that suggest that the treatment might benefit them. It’s just likely that the effect will not be as pronounced as the “cure” patients with younger CRPS might experience.”

Other bisphosphenates

Grünenthal’s announcement comes only 6 months after a multiple-centre trial of another bisphosphonate drug for the treatment of CRPS, Zoledronate (also known as Zoledronic Acid), was halted by the pharmaceutical company, Axsome Therapeutics. The reason given for halting that trial was “futility”; in other words, the data collected to that point suggested that the trial was not going to meet its objectives.

However, as we reported recently, the bisphosphonate Pamidronate, which more often is used to treat secondary bone cancer, continues to be used to also treat early stage CRPS. Indeed, in the UK, pain medicine consultants in some NHS Trusts are now referring patients with early stage CRPS for a infusions of Pamidronate whilst maintaining their general regime of medication and physical therapy.

In the meantime, the results of Grünenthal’s trials are awaited keenly.

You may also be interested in the following articles:

Hypnosis to treat CRPS: new research

Does immunotherapy treatment for CRPS have a future?

CRPS and menstruation

Can symptoms of CRPS be remitted using low-dose Naltrexone?

Stem Cell transplants – the next big step in CRPS treatment?

Richard Lowes
Make an Enquiry

Contact Us

Contact Form

Left Column

Right Column

Centre

 
Sending

Recent Articles

  • The law on accessible toilets
  • Taking medication abroad
  • CRPS and excessive sweating
  • The importance of medical records in your CRPS compensation claim
  • CRPS and sleep

Share this Article

Newsletter Sign-up

* indicates required

Legal Glossary

Find Out More

You may also like...

  • Jun 18th, 2018
    Medicinal Cannabis: THC vs CBD
    Read Article
  • Jul 4th, 2018
    CRPS and Allergies: coincidence or causal?
    Read Article
View All Related Articles

Get in Touch Today

Contact Form

Left Column

Right Column

Centre

 
Sending

1 Edgar Buildings,
George Street,
Bath, BA1 2DU

01225 462871 01225 445060
Authorised & Regulated by Solicitors Regulation Authority (No. 636644).
©2025 BLB Solicitors  |  Privacy & Terms